Clinical Trial Update: A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating OligoG in cystic fibrosis subjects with Burkholderia spp. infection has completed. The trial was sponsored by AlgiPharma AS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkholderia Infection
• Cystic Fibrosis

Drugs mentioned

• OligoG (oligoG)

Snippet

Sponsor: AlgiPharma AS | Conditions: Cystic Fibrosis, Burkholderia Infection | Phase 2 | Status: COMPLETED